Harvard Bioscience Net Income 2012-2026 | HBIO
Harvard Bioscience net income from 2012 to 2026. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
|
Harvard Bioscience Annual Net Income (Millions of US $) |
|
|---|---|
| 2025 | $-57 |
| 2024 | $-12 |
| 2023 | $-3 |
| 2022 | $-10 |
| 2021 | $0 |
| 2020 | $-8 |
| 2019 | $-5 |
| 2018 | $-3 |
| 2017 | $-1 |
| 2016 | $-4 |
| 2015 | $-19 |
| 2014 | $2 |
| 2013 | $-2 |
| 2012 | $2 |
| 2011 | $4 |
|
Harvard Bioscience Quarterly Net Income (Millions of US $) |
|
|---|---|
| 2026-03-31 | $-3 |
| 2025-12-31 | $-3 |
| 2025-09-30 | $-1 |
| 2025-06-30 | $-2 |
| 2025-03-31 | $-50 |
| 2024-12-31 | $0 |
| 2024-09-30 | $-5 |
| 2024-06-30 | $-3 |
| 2024-03-31 | $-5 |
| 2023-12-31 | $-2 |
| 2023-09-30 | $-1 |
| 2023-06-30 | $-1 |
| 2023-03-31 | $1 |
| 2022-12-31 | $-2 |
| 2022-09-30 | $-3 |
| 2022-06-30 | $2 |
| 2022-03-31 | $-7 |
| 2021-12-31 | $1 |
| 2021-09-30 | $0 |
| 2021-06-30 | $0 |
| 2021-03-31 | $-1 |
| 2020-12-31 | $-1 |
| 2020-09-30 | $-1 |
| 2020-06-30 | $-2 |
| 2020-03-31 | $-5 |
| 2019-12-31 | $1 |
| 2019-09-30 | $-3 |
| 2019-06-30 | $0 |
| 2019-03-31 | $-2 |
| 2018-12-31 | $3 |
| 2018-09-30 | $0 |
| 2018-06-30 | $-1 |
| 2018-03-31 | $-4 |
| 2017-12-31 | $1 |
| 2017-09-30 | $0 |
| 2017-06-30 | $0 |
| 2017-03-31 | $-1 |
| 2016-12-31 | $-1 |
| 2016-09-30 | $-2 |
| 2016-06-30 | $-1 |
| 2016-03-31 | $-1 |
| 2015-12-31 | $-17 |
| 2015-09-30 | $-1 |
| 2015-06-30 | $0 |
| 2015-03-31 | $-1 |
| 2014-12-31 | $0 |
| 2014-09-30 | $1 |
| 2014-06-30 | $1 |
| 2014-03-31 | $1 |
| 2013-12-31 | $-1 |
| 2013-09-30 | $-1 |
| 2013-06-30 | $0 |
| 2013-03-31 | $0 |
| 2012-12-31 | $1 |
| 2012-09-30 | $0 |
| 2012-06-30 | $1 |
| 2012-03-31 | $1 |
| 2011-12-31 | $1 |
| 2011-09-30 | $0 |
| 2011-06-30 | $1 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Computer and Technology | Scientific Instruments Manufacturing | $0.019B | $0.087B |
| HARVARD BIOSCIENCE develops, manufactures and markets tools used in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bruker (BRKR) | United States | $5.722B | 20.54 |
| Kewaunee Scientific (KEQU) | United States | $0.100B | 8.24 |